Skip to main content
SpringerLink
Log in

Alemtuzumab/Methylprednisolone

Thyroid eye disease and lack of efficacy

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Muller I, et al. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab. European Thyroid Journal 13: No. 2, Apr 2024. Available from: URL: https://dx.doi.org/10.1530/ETJ-23-0236

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab/Methylprednisolone. Reactions Weekly 2006, 27 (2024). https://doi.org/10.1007/s40278-024-57922-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-57922-y

Search

Navigation